Fig. 1From: Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot studyPsychosocial and clinical severity scores at baseline and 6-month follow-up. Mean scores for psychosocial and clinical severity assessments are shown for group 1 (A) and group 2 (B). CGI-S measures the clinical severity of a participantās illness, with a lower score indicating less severe disease. SSQ measures the degree of available social support and satisfaction with the social environment for each participant, with a higher score indicating higher levels of social support/satisfaction. CORE-10 measures levels of psychological distress, with a lower score indicating less distress. In group 2, three participants withdrew from treatment before 6-month follow-up and scores could not be collected. One further participant failed to complete the follow-up CORE-10 and SSQ assessment despite remaining on treatment, so was excluded from this analysis. Data shown are meanāĀ±āSD. Two-tailed, paired sample t-tests were used to determine statistical differencesBack to article page